Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial


Jukema J. W. , Szarek M., Zijlstra L. E. , de Silva H. A. , Bhatt D. L. , Bittner V. A. , ...Daha Fazla

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.74, sa.9, ss.1167-1176, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 74 Konu: 9
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jacc.2019.03.013
  • Dergi Adı: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
  • Sayfa Sayıları: ss.1167-1176

Özet

BACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined.